Clinical Trials
27 trialsNCT01366612 2026-04-03
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated
NCT04551066 2025-10-21
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation
Phase 3 Terminated
NCT04551053 2025-10-02
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Phase 3 Terminated
NCT03016130 2025-04-07
UF-BMT-LDND-101
University of Florida
Phase 3 Terminated
NCT03746054 2025-03-17
PALERMO
University Hospital, Angers
Phase 3 Terminated
NCT03755518 2024-12-12
FREEDOM
Celgene
Phase 3 Terminated
NCT04326764 2023-02-16
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University
Phase 3 Terminated
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01339910 2023-01-04
BMT CTN 0901
Medical College of Wisconsin
Phase 3 Terminated
NCT02999854 2022-05-24
HATCY
Kiadis Pharma
Phase 3 Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT02055781 2021-11-18
PAC326
CTI BioPharma
Phase 3 Terminated
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT02115386 2019-12-10
MACS1532
Novartis
Phase 3 Terminated
NCT02174445 2019-12-02
DECLINE
University Hospital Freiburg
Phase 3 Terminated
NCT02108951 2017-10-27
ENESTswift
Novartis
Phase 3 Terminated
NCT00324324 2017-05-09
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
OHSU Knight Cancer Institute
Phase 3 Terminated
NCT01749111 2017-03-03
CICLODECH
Hospital Israelita Albert Einstein
Phase 3 Terminated
NCT00004933 2016-07-04
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00109538 2015-05-01
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00089141 2013-05-03
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
Fred Hutchinson Cancer Center
Phase 3 Terminated
NCT01645124 2012-07-20
CYTO-PV
Consorzio Mario Negri Sud
Phase 3 Terminated
NCT00124748 2012-02-03
TOPS
Novartis
Phase 3 Terminated
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated
NCT00306332 2009-08-18
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
Radboud University Medical Center
Phase 3 Terminated